SII to launch QHPV vaccine against cervical cancer
India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India's (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).The Serum Institute of India's CEO Adar Poonawalla tweeted to make the announcement. "For the first time, there will be an Indian HPV vaccine to...
India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India's (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).
For more details, check out the full story on the link below:
FIRST: Serum Institute Gets DCGI Nod For QHPV Vaccine Against Cervical Cancer
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd